ClinicalTrials.gg
Active, not recruitingNCT07211685ASSESSUpdated Oct 29, 2026

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

A Phase 2 interventional study of BAY 3401016 and Placebo in Alport Syndrome, sponsored by Bayer. Active, not recruiting at 51 sites in 15 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Updated Oct 29, 20268 sites added15 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Nephritis, Hereditary with a site in United States — 5 open to participants now, 8 under way, none of them phase 3. Nephritis, Hereditary · United States.

Planned enrollment
6th of 11
60 · median 60
Started
2025
the only one that year
Phase 2
7 of 19
2 open now
Registered
17th of 19
by date
Lead sponsor
1 of 19
Bayer

Among the 19 studies in Nephritis, Hereditary with a site in United States, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 2, and was the 17th registered.

Nephritis, Hereditary

39 studies on the registry are indexed under Nephritis, Hereditary; 15 are open to participants now.

Browse Nephritis, Hereditary studies →

Open to participants now

5 of the 19 studies in Nephritis, Hereditary with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Nephritis, Hereditary studies recruiting now, 7 (64%) set no upper age limit and 3 (27%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Nephritis, Hereditary with a site in United States, or all of them as a file.
02

Study summary

Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a high risk of developing chronic kidney disease (CKD), a condition in which there is progressive loss in kidney function over time. The kidneys soon lose their ability to remove waste products from the body properly, resulting in end-stage kidney disease. A common sign of decreasing kidney function is the presence of excess protein in the urine that is not usually found with healthy kidneys. This condition is known as proteinuria. The study drug, BAY 3401016 (a monoclonal antibody), is a type of medicine that blocks a protein called Semaphorin 3A (Sema3A), which is thought to be involved in causing kidney damage in AS. By blocking the action of the Sema3A protein, BAY 3401016 may prevent proteinuria and slow down the loss in kidney function due to AS.

The main purpose of this study is to learn more about how well BAY 3401016 works in slowing down the loss in kidney function in adults with a rapidly progressing AS.

03

Conditions studied

  • Alport Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 to 45 years of age inclusive
  • Participants with AS, either XLAS (male) or ARAS (male or female)
  • ≥ 45 mL/min/1.73m2
  • UACR ≥ 500mg/g

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney disease is different from AS
  • illness that could have influence on the safety of the participant and/or interfere with the study objectives
  • History or current existence of
  • Participants with history of severe allergies, multiple drug allergies or non-allergic drug reactions including allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with or urticaria
  • Participants with active skin disorders (e.g. atopic dermatitis, severe acne)
  • Systolic blood pressure above 140 mmHg
  • Diastolic blood pressure above 90 mmHg
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    BAY 3401016

    BAY 3401016 weekly for 24 weeks in addition to background therapy if eligible

    Drug: BAY 3401016

  • Placebo comparator
    Placebo

    Placebo weekly for 24 weeks in addition to background therapy if eligible

    Other: Placebo

Interventions

  • DrugBAY 3401016

    BAY 3401016

  • OtherPlacebo

    Placebo to BAY 3401016

06

What researchers measure

Primary outcomes

  1. Urinary albumin creatinine ratio (UACR) ratio to baseline averaged over 16, 20 and 24 weeks of treatment

    Progression of kidney disease, including Alport Syndrome (AS), to End-Stage Renal Disease (ESRD) takes years, making it challenging to establish drug efficacy in clinical trials without long follow-ups or large sample sizes. Using surrogate endpoints, such as early changes in albuminuria, can help address this issue. It is tested wether BAY 3401016 has an effect on albuminuria in AS patients. Research shows that albumin overload leads to renal function decline and podocyte injury.

    Time frame: From the start of study intervention, over 16, 20 and 24 weeks of treatment, until the last follow-up visit, 90 days ± 3 days after EoT

Secondary outcomes

  1. Investigate the safety and tolerability of BAY 3401016 in participants with AS

    Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    Time frame: From the start of study intervention until the last follow-up visit, 90 days ± 3 days after EoT

07

Study locations

51 sites
  • Nephrology Clinic at The Kirklin Clinic of UAB Hospital
    Birmingham, Alabama 35233, United States
  • The Peggy and Harold Katz Family Drug Discovery Center - Nephrology
    Miami, Florida 33136, United States
  • Cardio Renal Institute
    Chubbuck, Idaho 83202, United States
  • Tufts Medical Center | Nephrology Department
    Boston, Massachusetts 02111, United States
  • Renal Disease Research Institute | Landry
    Dallas, Texas 75246, United States
  • Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares S.A.
    Santa Fe, Santa Fe Province S3000EPV, Argentina
  • Hospital Británico
    Buenos Aires, C1280AEB, Argentina
  • Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
    Buenos Aires, C1431FWO, Argentina
  • Centro de Rehabilitacion Cardiovascular | San Luis, Argentina
    San Luis, D5700CGR, Argentina
  • St Joseph's Healthcare Hamilton | Cardiology
    Hamilton, Ontario L8N 4A6, Canada
  • Montreal General Hospital | Nephrology
    Montreal, Quebec H4A 3J1, Canada
  • Centre hospitalier universitaire de Québec (CHUQ) | Nephrology
    Québec, G1R 2J6, Canada
  • Peking University First Hospital - Department of Pediatrics
    Beijing, Beijing Municipality 100000, China
  • The First Affiliated Hospital, Sun Yat-sen University - Department of Pediatrics
    Guangzhou, Guangdong 510080, China
  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology - Pediatric Nephrology and Immunology
    Wuhan, Hubei 430205, China
  • Children's Hospital, Zhejiang University School of Medicine - Department of Nephrology
    Hangzhou, Zhejiang 310052, China
  • Fakultní nemocnice Hradec Kralové - Nefrologická klinika
    Hradec Králové, Hradec Králové Region 500 05, Czechia
  • CHU de Brest - Hopital La Cavale Blanche - Service de Nephorologie-Hémodialyse-Transplantation
    Brest, Brittany Region 29200, France
  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital de Rangueil - Nephrologie et transplantation d'organes
    Toulouse, Occitanie 31400, France
  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Necker-Enfants Malades - Service d'Hopital De Jour Néphrologie adulte
    Paris, Île-de-France Region 75015, France
  • Universitaetsklinikum Erlangen - Medizinische Klinik 4, Nephrologie, Hypertensiologie
    Erlangen, Bavaria 91054, Germany
  • Universitaetsmedizin Goettingen (UMG) - Klinik fuer Nephrologie und Rheumatologie
    Göttingen, Lower Saxony 37075, Germany
  • Universitaetsklinikum Koeln - Klinik II fuer Innere Medizin - Nephrologie, Rheumatologie, Diabetologie, Innere Medizin
    Cologne, North Rhine-Westphalia 50937, Germany
  • Charité Mitte - Nephrologie und Internistische Intensivmedizin
    Berlin, 10117, Germany
  • Mavani Research Center
    Ahmedabad, Gujarat 380052, India
  • All India Institute of Medical Sciences (AIIMS) - New Delhi
    New Delhi, National Capital Territory of Delhi 110029, India
  • K.G. Hospital
    Coimbatore, Tamil Nadu 641018, India
  • The Institute of Post Graduate Medical Education & Research (IPGMER) (SSKM Hospital)
    Kolkata, West Bengal 700020, India
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto
    Bologna, Emilia-Romagna 40138, Italy
  • Ospedale Pediatrico Bambino Gesù - Nefrologia
    Rome, Lazio 00165, Italy
  • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene
    Genoa, Liguria 16147, Italy
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia
    Brescia, Lombardy 25123, Italy
  • Japanese RedCross Aichi Medical Center Nagoya Daini Hospital
    Nagoya, Aichi-ken 466-8650, Japan
  • Saitama Prefectural Children's Medical Center
    Chuo-Ku, Tokyo 330-8777, Japan
  • Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital
    Osaka, 534-0021, Japan
  • Uniwersytecki Szpital Kliniczny w Poznaniu - Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych
    Poznan, Greater Poland Voivodeship 60-355, Poland
  • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy - Centrum Wsparcia Badań Klinicznych
    Warsaw, Masovian Voivodeship 04-141, Poland
  • Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department
    Vila Nova de Gaia, Porto District 4434-502, Portugal
  • Hospital de Torres Novas - Nephrology Department
    Torres Novas, Santarém District 2350-399, Portugal
  • Hospital de Curry Cabral - Nephrology Department
    Lisbon, 1069-166, Portugal
  • Unidade Local de Saúde de São João E.P.E. - Hospital São João - Serviço de Nefrologia
    Porto, 4200-319, Portugal
  • Seoul National University Bundang Hospital | Nephrology
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Seoul National University Hospital | Nephrology
    Seoul, 03080, South Korea
  • Hospital Universitari Vall D Hebron | Nefrologia
    Barcelona, Catalonia 08035, Spain
  • Hospital General La Mancha Centro | Nefrologia
    Alcázar de San Juan, Ciudad Real 13600, Spain
  • Hospital Universitario Fundacion Jimenez Diaz | Nephrology and Hypertension Department
    Madrid, 28040, Spain
  • Hospital Universitario Virgen Del Rocio S.L. | Nefrologia
    Seville, 41013, Spain
  • Royal Devon and Exeter Hospital | Renal Unit
    Exeter, Devon EX2 5DW, United Kingdom
  • Royal Free Hospital | Centre for Nephrology
    London, Greater London NW3 2QG, United Kingdom
  • Northern General Hospital | Sheffield Kidney Institute
    Sheffield, South Yorkshire S5 7AU, United Kingdom
  • Sunderland Royal Hospital | Renal Unit
    Sunderland, Tyne and Wear SR4 7TP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Oct 8, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Nov 29, 2027
CompletionEst.
Nov 29, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 15 sites removed
Show 8 added (4 Italy, 2 Poland, 1 Portugal, 1 Spain)
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto · Bologna, Italy
  • Ospedale Pediatrico Bambino Gesù - Nefrologia · Rome, Italy
  • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genoa, Italy
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia · Brescia, Italy
  • Uniwersytecki Szpital Kliniczny w Poznaniu - Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych · Poznan, Poland
  • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy - Centrum Wsparcia Badań Klinicznych · Warsaw, Poland
  • Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department · Vila Nova de Gaia, Portugal
  • Hospital Universitari Vall D Hebron | Nefrologia · Barcelona, Spain
Show 15 removed
  • Center for Advanced Pediatrics - Nephrology · Atlanta, United States
  • University Hospital | Nephrology · London, Canada
  • Lakeridge Health | Nephrology · Whitby, Canada
  • Children's Hospital of Chongqing Medical University - Department of Nephrology · Chongqing, China
  • Všeobecná fakultní nemocnice v Praze - Klinika nefrologie · Prague, Czechia
  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto · Bologna, Italy
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia · Brescia, Italy
  • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genova, Italy
  • Ospedale Pediatrico Bambino Gesù - Nefrologia · Roma, Italy
  • Kobe University Hospital · Kobe, Japan
  • Uniwersytecki Szpital Kliniczny w Poznaniu - Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych · Poznan, Poland
  • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy - Centrum Wsparcia Badań Klinicznych · Warsaw, Poland
  • Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department · Vila Nova de Gaia, Portugal
  • Hospital Universitari Vall D Hebron | Nefrologia · Barcelona, Spain
  • Fundacio Puigvert | Nefrologia · Barcelona, Spain
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    8 sites added, 15 sites removed
    Show 8 added (4 Italy, 2 Poland, 1 Portugal, 1 Spain)
    • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto · Bologna, Italy
    • Ospedale Pediatrico Bambino Gesù - Nefrologia · Rome, Italy
    • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genoa, Italy
    • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia · Brescia, Italy
    • Uniwersytecki Szpital Kliniczny w Poznaniu - Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych · Poznan, Poland
    • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy - Centrum Wsparcia Badań Klinicznych · Warsaw, Poland
    • Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department · Vila Nova de Gaia, Portugal
    • Hospital Universitari Vall D Hebron | Nefrologia · Barcelona, Spain
    Show 15 removed
    • Center for Advanced Pediatrics - Nephrology · Atlanta, United States
    • University Hospital | Nephrology · London, Canada
    • Lakeridge Health | Nephrology · Whitby, Canada
    • Children's Hospital of Chongqing Medical University - Department of Nephrology · Chongqing, China
    • Všeobecná fakultní nemocnice v Praze - Klinika nefrologie · Prague, Czechia
    • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto · Bologna, Italy
    • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia · Brescia, Italy
    • IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene · Genova, Italy
    • Ospedale Pediatrico Bambino Gesù - Nefrologia · Roma, Italy
    • Kobe University Hospital · Kobe, Japan
    • Uniwersytecki Szpital Kliniczny w Poznaniu - Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych · Poznan, Poland
    • Wojskowy Instytut Medyczny Państwowy Instytut Badawczy - Centrum Wsparcia Badań Klinicznych · Warsaw, Poland
    • Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department · Vila Nova de Gaia, Portugal
    • Hospital Universitari Vall D Hebron | Nefrologia · Barcelona, Spain
    • Fundacio Puigvert | Nefrologia · Barcelona, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07211685
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Nov 19, 2025
Primary completion
Nov 29, 2027 (estimated)
Completion
Nov 29, 2027 (estimated)
Last update
Oct 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion